Reason for request
Extension of indication
Clinical Benefit
Clinical Added Value
| no clinical added value |
" In view of : - the efficacy and safety data versus placebo, - the absence of direct comparative data versus other anti-ANF agents, particularly infliximab, the Transparency Committee considers that SIMPONI (golimumab) does not provide any improvement in actual benefit (IAB V, non-existent) in the treatment of moderately to severely active UC which is resistant to conventional therapies." |
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
aMNjaqXSZ0rHwJXg
